论文信息 - Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial - 字舞流文

Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Michael L. Wang | C. Jacobson | J. Rossi | F. Locke | A. Goy | B. Hill | P. Reagan | A. Bot | S. Jaglowski | I. Kloos | H. Holmes | J. Muñoz | W. Peng | Lianqing Zheng | A. Xue | X. Fang